Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Mark Eisner sold 3,586 shares of the firm's stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $5.47, for a total value of $19,615.42. Following the sale, the executive vice president directly owned 104,618 shares of the company's stock, valued at $572,260.46. This represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mark Eisner also recently made the following trade(s):

• On Tuesday, July 15th, Mark Eisner sold 6,796 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.47, for a total transaction of $37,174.12.

Vir Biotechnology Price Performance

Vir Biotechnology stock traded up $0.08 during mid-day trading on Thursday, hitting $5.49. The company's stock had a trading volume of 1,282,059 shares, compared to its average volume of 1,369,327. The business has a 50 day moving average price of $5.13 and a 200-day moving average price of $6.97. The stock has a market cap of $758.94 million, a price-to-earnings ratio of -1.30 and a beta of 1.22. Vir Biotechnology, Inc. has a 12 month low of $4.32 and a 12 month high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative return on equity of 47.46% and a negative net margin of 2,769.04%. The company had revenue of $3.03 million during the quarter, compared to the consensus estimate of $8.59 million. During the same quarter last year, the company posted ($0.48) earnings per share. The firm's revenue for the quarter was down 94.6% compared to the same quarter last year. On average, equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and issued a $14.00 price target on shares of Vir Biotechnology in a report on Thursday, May 22nd. Raymond James Financial initiated coverage on Vir Biotechnology in a report on Friday, July 11th. They issued an "outperform" rating for the company. Finally, The Goldman Sachs Group reduced their target price on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $30.25.

Institutional Trading of Vir Biotechnology

Several large investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vir Biotechnology in the 4th quarter worth $42,000. GAMMA Investing LLC boosted its stake in shares of Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock worth $46,000 after buying an additional 5,972 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after acquiring an additional 1,999 shares during the period. Syon Capital LLC purchased a new stake in Vir Biotechnology during the fourth quarter valued at $77,000. Finally, FORA Capital LLC bought a new position in Vir Biotechnology in the first quarter valued at about $70,000. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.